Nuvation Bio Inc.
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
About Nuvation Bio
Pharmaceutical Preparations, SIC 2834
Nuvation Bio Inc. is a biopharmaceutical company that develops and commercializes targeted therapies for cancer patients. The company operates within the oncology sector, discovering and advancing small-molecule treatments and drug-drug conjugates. Its lead commercial medicine is IBTROZI, an oral ROS1 inhibitor approved for adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer. Additionally, the company advances a clinical pipeline that includes safusidenib for patients with IDH1-mutant brain tumors, along with early-stage candidates designed through its drug-drug conjugate platform.
The company operates on an international scale, marketing its lead therapy in the United States and collaborating with regional pharmaceutical partners to commercialize treatments in Japan, China, Europe, and numerous other territories. Its United States commercial footprint includes seventy-one commercial field staff and seven medical affairs representatives. The enterprise owns no manufacturing facilities, relying instead on third-party contract manufacturers for product supply. The provided text does not disclose the location of the company's corporate headquarters.
Summary of the business section of Nuvation Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nuvation Bio Inc.
- Founded
- 2018
- Headquarters
- New York, NY
- Address
- 1500 Broadway, Suite 1401 10036
- Phone
- (332) 208-6102
- Employees
- 298, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, New York, NY
Stock & identifiers
- Ticker
- NUVB
- Exchange
- NYSE
- IPO date
- Jul 2, 2020
- Shares outstanding
- 351M, Aug 3, 2026
- Public float
- $496.97M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1811063
- CUSIP
- 67080N101
- ISIN
- US67080N1019
- LEI
- 2549009IT4XP2SCZTR55
- EIN
- 85-0862255
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Hung | PRESIDENT AND CEO, Director | 60,281,054 |
| Junyuan Jerry Wang | CEO, ANHEART THERAPEUTICS LTD., Director | 6,112,686 |
| Gary Hattersley | CHIEF SCIENTIFIC OFFICER | 0 |
| Philippe Sauvage | Chief Financial Officer | 54,130 |
| Stacy Markel | CHIEF PEOPLE OFFICER | 157,591 |
| Kerry Wentworth | CHIEF REGULATORY OFFICER | 116,000 |
| Dongfang Liu | CHIEF MEDICAL OFFICER | 68,000 |
| Colleen Sjogren | Chief Commercial Officer | 84,000 |
| David C. Hanley | CHIEF TECHNICAL OPERATIONS | 24,000 |
| Moses Makunje | SEE REMARKS | 68,137 |
| Robert Mashal | Director | 225,000 |
| W. Anthony Vernon | Director | 254,100 |
| Robert B. Bazemore | Director | 5,000 |
| Kathryn E. Falberg | Director | 250,000 |
| Kim D. Blickenstaff | Director | 172,189 |
| Xiangmin Cui | Director | 25,954,439 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David Hung, M.D. | $3.88M | $27.83M | $1.48M | $77 | – |
| FY2024 David Hung, M.D. | $3.72M | $6.54M | $1.79M | $23 | – |
| FY2023 David Hung, M.D. | $4.32M | $2.79M | $1.35M | $13 | – |
| FY2022 David Hung, M.D. | $8.07M | $1.91M | $3.64M | $16 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 298 full-time employees, 58 of whom hold Ph.Ds, M.Ds or Pharm.Ds.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 10, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| Apr 10, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 12, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 12, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 12, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 11, 2021 | Name change | Name changed from Panacea Acquisition Corp to Nuvation Bio Inc. |
| Feb 11, 2021 | Delisting | Notice of delisting from exchange (Form 25) |
| Nov 12, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jul 2, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 26, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |